ETP 50 mg (Tablet)
Unit Price: ৳ 909.02 (1 x 7: ৳ 6,363.14)
Strip Price: ৳ 6,363.14
Medicine Details
| Category | Details |
|---|---|
| Generic | Eltrombopag olamine |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
- Treatment of thrombocytopenia in patients with hepatitis C infection
- Treatment of severe aplastic anemia
Pharmacology
Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist that interacts with the transmembrane domain of the human TPO-receptor.
Dosage & Administration
- Route of administration: Oral route
- Recommended dose for different conditions:
- 50 mg once daily for persistent or chronic immune thrombocytopenia
- 25-50 mg once daily for adult and pediatric patients with ITP
- 25 mg once daily for pediatric patients with ITP aged 1 to 5 years
- 25-100 mg once daily for chronic hepatitis C associated thrombocytopenia
- 2.5 mg/kg for first line severe aplastic anemia
- 50-150 mg once daily for refractory severe aplastic anemia
- Dosage adjustment based on patient characteristics: Dose adjustment for patients of Asian ancestry or those with hepatic impairment
Interaction
- Drug interaction with medication: Take eltrombopag at least 2 hours before or 4 hours after any medications or products containing polyvalent cations
- Drug interaction with food and others: Take eltrombopag at least 2 hours before or 4 hours after any calcium rich foods
Contraindications
Known hypersensitivity to eltrombopag or any components of the product
Side Effects
- Anemia
- Nausea
- Pyrexia
- ALT increased
- Cough
- Fatigue
- Headache
- Diarrhea
Pregnancy & Lactation
- Effects on pregnancy: No sufficient data available to assess drug-associated risks for major birth defects, miscarriage or adverse maternal or fetal outcomes
- Effects on breastfeeding: Not recommended due to potential for serious adverse reactions in a breastfed child
Precautions & Warnings
- Hepatitis C combination therapy: Increased risk of hepatic decompensation
- Myelodysplastic syndromes: Risk of death and progression to acute myeloid leukemia
- Portal vein thrombosis: Reported in patients with chronic liver disease receiving eltrombopag
- Monitoring: Regular monitoring of liver function and platelet counts
Use in Special Populations
- Use in children and adolescents: Safety and efficacy not established for pediatric patients below the age of 1 year and with certain conditions
Overdose Effects
Excessive increase in platelet counts leading to thrombotic complications
Therapeutic Class
Haemostatic drugs
Storage Conditions
Store in a cool and dry place protected from light. Keep away from the reach of children